Holen Sie sich die Stockscreener-App
5.06
1.75%
-0.09
Sagimet Biosciences Inc Aktie (SGMT) Neueste Nachrichten
Top Sagimet Executives Quietly Unload Shares in Coordinated Insider Move - TipRanks
David Happel Sells 12,101 Shares of Sagimet Biosciences (NASDAQ:SGMT) Stock - MarketBeat
Is Sagimet Biosciences Inc. stock trending bullish2025 Volume Leaders & Free Safe Capital Growth Stock Tips - mfd.ru
Is Sagimet Biosciences Moving Closer to Market-Ready Treatments - Kalkine Media
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences - The Manila Times
Hear Sagimet Biosciences at Guggenheim and Oppenheimer investor events - Stock Titan
A Look At Sagimet Biosciences (SGMT) Valuation After Denifanstat’s Phase 3 Acne Trial Success - Yahoo Finance
Analysts Are Bullish on These Healthcare Stocks: Thermo Fisher (TMO), Tenet Healthcare (THC) - The Globe and Mail
Sagimet Biosciences (NASDAQ:SGMT) Coverage Initiated by Analysts at Guggenheim - Defense World
After Clearing Up Acne, Sagimet Stock Rises - Barron's
Sagimet a new buy at Guggenheim on promise of MASH, acne asset - Seeking Alpha
Sagimet Biosciences (NASDAQ:SGMT) Earns Buy Rating from Analysts at Guggenheim - MarketBeat
Sagimet Biosciences' (SGMT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
New acne mechanism shows 1-year durability in Phase III, says Sagimet - The Pharma Letter
Sagimet Therapeutics: Strengthened FASN-Inhibition Safety Profile and Advancing Phase 2 Programs Support Buy Rating - TipRanks
Sagimet stock rises after positive Phase 3 safety data for acne drug By Investing.com - Investing.com South Africa
Sagimet stock rises after positive Phase 3 safety data for acne drug - Investing.com Australia
Sagimet Biosciences announces license partner Ascletis issues results for ASC40 - TipRanks
Sagimet Biosciences Reports Positive Phase 3 Acne Data - TipRanks
Sagimet Biosciences Inc Announces Positive Phase 3 Acne Trial Results - TradingView
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne - The Manila Times
Sagimet’s Denifanstat: China Phase III Safety Data Isn’t A Negative Signal (NASDAQ:SGMT) - Seeking Alpha
Sagimet down as Chinese partner posts late-stage trial data for acne therapy - MSN
Sagimet Biosciences (NASDAQ:SGMT) Stock Rating Upgraded by Barclays - MarketBeat
Once-a-day acne pill shows 40-week safety in 240 Chinese patients - stocktitan.net
Barclays Initiates Coverage of Sagimet Biosciences (SGMT) with Equal-Weight Recommendation - Nasdaq
Barclays Initiates Coverage on Sagimet Biosciences With Equal Weight Rating, $8 Price Target - marketscreener.com
Is Sagimet Biosciences Inc stock influenced by commodity pricesWeekly Profit Analysis & Reliable Breakout Forecasts - baoquankhu1.vn
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Sagimet Biosciences enters global license agreement with TAPI - MSN
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Sagimet Biosciences (NASDAQ:SGMT) Shares Down 0.5%Here's Why - MarketBeat
Trend Review: Can Sagimet Biosciences Inc deliver alphaWeekly Market Outlook & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Will Sagimet Biosciences Inc stock keep outperforming rivalsJuly 2025 WrapUp & Fast Entry High Yield Tips - Bộ Nội Vụ
Death Cross: Can Sagimet Biosciences Inc stock reach 100 price targetPortfolio Risk Summary & High Return Trade Opportunity Guides - Bộ Nội Vụ
Sagimet Biosciences: Advancing FASN Inhibitor Pipeline and Multi-Indication Opportunities Support Buy Rating and $26 Target - TipRanks
Why Sagimet Biosciences Inc. stock remains on watchlistsJuly 2025 Recap & AI Powered Market Entry Strategies - Улправда
After-Hours Biotech Gainers: RVMD Soars On Merck Deal Talks Reports, SXTC, KALV, SGMT Rally - RTTNews
How Sagimet Biosciences Inc. stock performs in stagflationJuly 2025 Fed Impact & Verified Short-Term Plans - Улправда
Why retail investors favor Sagimet Biosciences Inc. stockQuarterly Investment Review & AI Based Buy and Sell Signals - Улправда
Why Sagimet Biosciences Inc. stock could be next big winnerRisk Management & Reliable Breakout Forecasts - Улправда
Can Sagimet Biosciences Inc. stock beat market expectations this quarterJuly 2025 PreEarnings & AI Driven Price Forecasts - Улправда
Published on: 2026-01-08 19:16:00 - Улправда
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference - The Manila Times
Falcon Technoprojects India Limited Chart Enters High Volatility ZoneTake Profit Strategies & Fast Growing Trading Ideas - earlytimes.in
Sagimet Biosciences Inc. (SGMT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
We're Hopeful That Sagimet Biosciences (NASDAQ:SGMT) Will Use Its Cash Wisely - Yahoo Finance
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Analysts Conflicted on These Healthcare Names: Moderna (MRNA), Disc Medicine (IRON) and Sagimet Biosciences, Inc. Class A (SGMT) - The Globe and Mail
JonesTrading Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $26 - 富途牛牛
Sagimet rises as licensing deal with Teva unit targets Madrigal drug - MSN
3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts - TipRanks
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):